• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.人型支原体和脲原体对新型研究性酮内酯类药物CEM-101的体外敏感性比较
Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.
2
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.新型氟喹诺酮类药物DC-159a与其他抗菌药物对人支原体和脲原体的体外活性比较
Antimicrob Agents Chemother. 2008 Oct;52(10):3776-8. doi: 10.1128/AAC.00849-08. Epub 2008 Jul 28.
3
Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.研究性肽脱甲酰酶抑制剂NVP LBM-415与其他药物对人支原体和脲原体的体外活性比较
Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. doi: 10.1128/AAC.49.6.2541-2542.2005.
4
Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.苯并喹喔啉氟喹诺酮类左氧氟沙星（WCK 771）和其他抗菌药物对人类支原体和脲原体的活性，包括具有明确耐药机制的分离株。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01348-18. Print 2018 Nov.
5
Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.格帕沙星（GSK2140944）及其他抗菌药物对人型支原体和脲原体的活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01064-17. Print 2017 Oct.
6
In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.AZD0914对人支原体和脲原体的体外抗菌活性。
Antimicrob Agents Chemother. 2015;59(6):3627-9. doi: 10.1128/AAC.04945-14. Epub 2015 Mar 30.
7
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.新型氟喹诺酮类药物ABT-492与其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性比较
Antimicrob Agents Chemother. 2003 Dec;47(12):3973-5. doi: 10.1128/AAC.47.12.3973-3975.2003.
8
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.ABT-773及其他抗菌药物对人型支原体的体外活性
Antimicrob Agents Chemother. 2003 Jan;47(1):39-42. doi: 10.1128/AAC.47.1.39-42.2003.
9
Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis.莫西沙星对泌尿生殖支原体脲原体属、人型支原体、生殖支原体及沙眼衣原体的活性。
Clin Microbiol Infect. 2008 Aug;14(8):801-5. doi: 10.1111/j.1469-0691.2008.02027.x.
10
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.加替沙星（BMS - 284756）及其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.

引用本文的文献

1
The Current Landscape of Antibiotic Use and Antimicrobial Resistance in Japan: Focusing on Common Infections Including Uncomplicated Urinary Tract Infection and Gonorrhea.日本抗生素使用与抗菌药物耐药性的现状：聚焦于包括单纯性尿路感染和淋病在内的常见感染
Antibiotics (Basel). 2025 Aug 8;14(8):813. doi: 10.3390/antibiotics14080813.
2
antimicrobial susceptibility of isolates across different regions of China in 2023.2023年中国不同地区分离株的抗菌药物敏感性
JAC Antimicrob Resist. 2025 Jul 30;7(4):dlaf124. doi: 10.1093/jacamr/dlaf124. eCollection 2025 Aug.
3
pneumonia in children.儿童肺炎
World J Clin Cases. 2025 Feb 16;13(5):99149. doi: 10.12998/wjcc.v13.i5.99149.
4
Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia.儿童肺炎支原体肺炎治疗面临的挑战。
Eur J Pediatr. 2024 Jul;183(7):3001-3011. doi: 10.1007/s00431-024-05519-1. Epub 2024 Apr 18.
5
Research status and challenges of Mycoplasma pneumoniae pneumonia in children: A bibliometric and visualization analysis from 2011 to 2023.儿童肺炎支原体肺炎的研究现状及挑战：2011 年至 2023 年的文献计量学和可视化分析。
Medicine (Baltimore). 2024 Mar 15;103(11):e37521. doi: 10.1097/MD.0000000000037521.
6
Potentially inappropriate prescribing in hospitalised children: a retrospective, cross-sectional study at a tertiary children's hospital in China.中国一家三级儿童医院住院儿童潜在不适当处方的回顾性横断面研究。
BMJ Open. 2023 May 2;13(5):e068680. doi: 10.1136/bmjopen-2022-068680.
7
Hyperammonemia in a septic patient with Ureaplasma parvum arthritis: a case report.脓毒症合并解脲脲原体关节炎患者的高血氨血症：一例报告。
BMC Infect Dis. 2022 Dec 22;22(1):958. doi: 10.1186/s12879-022-07953-8.
8
Construction of a Nomogram for Identifying Refractory Pneumonia Among Macrolide-Unresponsive Pneumonia in Children.构建用于识别儿童大环内酯类无反应性肺炎中难治性肺炎的列线图
J Inflamm Res. 2022 Nov 30;15:6495-6504. doi: 10.2147/JIR.S387809. eCollection 2022.
9
Traditional Chinese Medicine Oral Liquids Combined With Azithromycin for Pneumonia in Children: A Bayesian Network Meta-Analysis.中药口服液联合阿奇霉素治疗儿童肺炎：一项贝叶斯网络Meta分析
Front Pharmacol. 2021 May 28;12:652412. doi: 10.3389/fphar.2021.652412. eCollection 2021.
10
A multisite SNP genotyping and macrolide susceptibility gene method for based on MALDI-TOF MS.一种基于基质辅助激光解吸电离飞行时间质谱的多位点单核苷酸多态性基因分型及大环内酯类药敏基因方法。
iScience. 2021 Apr 16;24(5):102447. doi: 10.1016/j.isci.2021.102447. eCollection 2021 May 21.

本文引用的文献

1
Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.CEM-101 对呼吸道病原体的抗菌特性研究，包括对多药耐药性肺炎球菌 19A 血清型分离株的研究。
Int J Antimicrob Agents. 2010 Jun;35(6):537-43. doi: 10.1016/j.ijantimicag.2010.01.026. Epub 2010 Mar 7.
2
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.新型氟喹诺酮类抗生素 CEM-101 对沙眼衣原体和肺炎衣原体（衣原体属）的体外活性。
Antimicrob Agents Chemother. 2010 Mar;54(3):1358-9. doi: 10.1128/AAC.01343-09. Epub 2009 Dec 28.
3
Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates.儿童肺炎支原体新出现的大环内酯类耐药性：耐药菌株的检测与特征分析
Pediatr Infect Dis J. 2009 Aug;28(8):693-6. doi: 10.1097/INF.0b013e31819e3f7a.
4
Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance.阿奇霉素治疗解脲脲原体阳性的非淋菌性尿道炎患者失败与诱导产生大环内酯类耐药有关。
Clin Infect Dis. 2008 Dec 15;47(12):1546-53. doi: 10.1086/593188.
5
Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.通过实时聚合酶链反应和高分辨率熔解分析检测肺炎支原体中的大环内酯类耐药性。
Antimicrob Agents Chemother. 2008 Oct;52(10):3542-9. doi: 10.1128/AAC.00582-08. Epub 2008 Jul 21.
6
Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.社区获得性肺炎儿科患者中肺炎支原体对大环内酯类药物耐药性增加。
Antimicrob Agents Chemother. 2008 Jan;52(1):348-50. doi: 10.1128/AAC.00779-07. Epub 2007 Oct 22.
7
First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years.法国12年间分离的肺炎支原体临床菌株中耐大环内酯类菌株的首次报告及P1黏附素基因新核苷酸序列变异的描述
J Clin Microbiol. 2007 Nov;45(11):3534-9. doi: 10.1128/JCM.01345-07. Epub 2007 Sep 19.
8
Fluoroquinolone resistance in Ureaplasma parvum in the United States.美国微小脲原体对氟喹诺酮类药物的耐药性。
J Clin Microbiol. 2006 Apr;44(4):1590-1. doi: 10.1128/JCM.44.4.1590-1591.2006.
9
Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae.大环内酯类耐药肺炎支原体的临床评估
Antimicrob Agents Chemother. 2006 Feb;50(2):709-12. doi: 10.1128/AAC.50.2.709-712.2006.
10
Mycoplasmas and ureaplasmas as neonatal pathogens.支原体和脲原体作为新生儿病原体
Clin Microbiol Rev. 2005 Oct;18(4):757-89. doi: 10.1128/CMR.18.4.757-789.2005.

人型支原体和脲原体对新型研究性酮内酯类药物CEM-101的体外敏感性比较

Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.

作者信息

Waites Ken B, Crabb D M, Duffy Lynn B

机构信息

Department of Pathology, 619 19th Street South, WP 230, University of Alabama at Birmingham, Birmingham, AL 35249, USA.

出版信息

Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.

DOI:10.1128/AAC.00090-09
PMID:19258276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2681567/
Abstract

MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at < or = 0.5 microg/ml, making CEM-101 the most potent compound tested.

摘要

测定了新型酮内酯类药物CEM - 101以及阿奇霉素、泰利霉素、多西环素、左氧氟沙星、克林霉素和利奈唑胺对36株肺炎支原体、5株生殖支原体、13株人型支原体、15株发酵支原体和20株脲原体分离株的最低抑菌浓度（MIC）。所有分离株，包括两株对大环内酯类耐药的肺炎支原体分离株，均被CEM - 101在≤0.5微克/毫升浓度下抑制，这使得CEM - 101成为所测试的最有效的化合物。